Uneven Frontiers

X · 3 months ago · 24

AI is expected to accelerate and reduce costs in certain areas of drug development, but clinical trials will remain a significant bottleneck because recruiting patients and collecting long-term safety data cannot be substantially sped up by artificial intelligence. The physical and regulatory constraints of human testing create a ceiling on how much AI can improve the overall timeline and cost of bringing new drugs to market. Consequently, AI's impact on pharma will be uneven, transforming discovery and early research while leaving late-stage development largely unchanged.